Medtronic Implantable Cardioverter Defibrillators Recalled for Potential Therapy Failure
Medtronic is recalling 661 CRT-D implantable defibrillators due to a rare manufacturing defect that may reduce or eliminate energy output during therapy delivery. Affected devices may fail to deliver necessary electrical treatment during cardiac emergencies.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA Class I designation mandates a minimum severity rating of 4. The recalled implantable defibrillators pose a risk of therapeutic failure in life-threatening cardiac situations. Although no illnesses or injuries are explicitly reported in the source, the potential for device failure to deliver life-saving therapy is inherently serious.
Plain-English summary
Medtronic, Inc. is recalling 661 CRT-D (cardiac resynchronization therapy defibrillator) devices, Model DTBA1D4 VIVA XT IS1/DF4 US. These are implantable cardioverter defibrillators designed to monitor heart rhythm and deliver electrical therapy when dangerous arrhythmias occur.
The recall addresses a rare manufacturing defect in a specific feedthrough component. This defect may result in reduced or no energy output during high-voltage therapy (typically 0–12 joules). The affected devices were distributed nationwide in the United States and worldwide.
Patients with these devices are at risk if dangerous cardiac arrhythmias occur and the device fails to deliver necessary electrical treatment. The FDA classified this as a Class I recall. Patients should contact their healthcare provider to determine if their device is affected.
The recalled product
- Product
- CRT-D DTBA1D4 VIVA XT IS1/DF4 US, Model Number DTBA1D4; Implantable Cardioverter Defibrillators
- Affected units
- 661
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- GTIN 00643169720251
- Lot Serial Numbers: BLE221424H
- BLE221443H
- BLE221244H
- BLE221357H
- BLE221415H
- BLE221487H
- BLE221190H
- BLE221267H
- BLE221842H
- BLE221265H
- BLE221430H
- BLE221711H
- BLE221346H
- BLE221631H
- BLE221285H
- BLE221405H
- BLE221436H
- BLE221551H
- BLE221411H
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 120 recalled by Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF) under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 120 products in this recall →Related recalls
Same manufacturer · Medtronic Inc., Cardiac Rhythm and Heart Failure (CRHF)
See all →- CriticalMedtronic CRT-D Defibrillators: Rare Energy Output Failure Risk During Therapy
FDA (Devices) · 2023-06-28
- SevereMedtronic Implantable Cardioverter Defibrillators Recalled for Reduced Therapy Output
FDA (Devices) · 2023-06-28
- SevereMedtronic Implantable Defibrillators Recalled for Potential Therapy Delivery Failure
FDA (Devices) · 2023-06-28
- SevereImplantable Cardioverter Defibrillators at Risk of Reduced Energy Output
FDA (Devices) · 2023-06-28
- SevereMedtronic Implantable Cardioverter Defibrillator may lose energy output during therapy
FDA (Devices) · 2023-06-28
Same hazard · therapeutic failure
See all →- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
- ModerateLevothyroxine Sodium Tablets 50 mcg Recalled for Subpotency
FDA (Drugs) · 2025-05-07
- HighLevothyroxine Sodium Tablets 88 mcg Recall for Subpotency
FDA (Drugs) · 2025-05-07
- ModeratePrescription Drug Tizanidine Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2023-07-12
- HighPrescription Levothyroxine Sodium Oral Solution Nationwide Recall Due to Subpotency
FDA (Drugs) · 2023-03-01